Predictors and outcomes of scleroderma renal crisis: Data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial

Arthritis and Rheumatism

Volumn 46, Issue 11, 2002, Pages 2836-2837

  Strand, Vibeke ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PENICILLAMINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; EDITORIAL; ELECTROCARDIOGRAM; FOLLOW UP; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; SYSTEMIC SCLEROSIS;

HUMANS; KIDNEY DISEASES; PENICILLAMINE; RANDOMIZED CONTROLLED TRIALS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 0036847085     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10602     Document Type: Editorial

References (15)

1. DeMarco PJ, Weisman MD, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al. Predictors and outcomes of scleroderma renal crisis: The High-dose Versus Low-dose D-Penicillamine in Early Diffuse Systemic Sclerosis trial. Arthritis Rheum 2002;46:2983-9.
2. Steen VD, Medsger TA Jr, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779-86.
3. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: Relationship to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.
4. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9.
5. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visit. Arthritis Rheum 1999;42:2660-5.
6. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
7. Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. Correlates of the Disability Index of the Health Assessment Questionnaire: A measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999;42:2372-80.
8. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445-54.
9. Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose D-penicillamine in systemic sclerosis trial. Arthritis Rheum 2001;44:653-61.
10. Altman RD, Medsger TA, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403-13.
11. Geirsson AJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: Using a modified Medsger scale. Ann Rheum Dis 2001;60:1117-22.
12. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
13. Gelber AC, Wigley FM. Disease severity as a predictor of outcome in scleroderma. Lancet 2002;359:277-9.
14. Jimenez SA, Varga J. Interferon gamma in systemic sclerosis: Biologic agents in autoimmune disease. In: Proceedings: Early Decision in DMARD Development II. Atlanta: Arthritis Foundation; 1991. p. 103-10.
15. Bulpitt KJ, Clements PJ, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS, et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993;118:602-9.